Insulin resistance and hyperinsulinaemia are associated with hypertension although a causative relationship has not been established. The aim of this study was to determine whether a short term reduction in insulin sensitivity induced by nicotinic acid treatment (NA) would alter blood pressure. The study was a double-blind randomised placebo-controlled cross-over study. Seven healthy volunteers, three males and four females were randomised to placebo or NA 500 mg daily for 7 days then 1 g daily for a further 7 days. Hyperinsulinaemic euglycaemic clamp, indirect calorimetry, 24-h ambulatory blood pressure monitoring (ABPM) and forearm blood flow measurement (FABF) were performed at day 14 of each treatment phase. NA significantly reduced the glucose infusion rate required to maintain euglycaemia in all subjects (placebo vs NA; 31.5 ± 4.2 vs
Introduction
Essential hypertension is an insulin resistant state characterised by impaired non-oxidative glucose disposal in skeletal muscle and fasting hyperinsulinaemia.
1,2 Although a close association between insulin resistance and hypertension has been observed in epidemiological studies, [2] [3] [4] [5] a causative relationship has not been established. In support of the hypothesis that insulin resistance may cause hypertension are observations that improving insulin sensitivity by weight loss or by pharmacological therapy without weight loss may reduce blood pressure. 6, 7 Furthermore, insulin has a number of physiological effects such as sodium retention, 8, 9 stimulation of the sympathetic nervous system 10 and increased intracellular cation concentrations 11 which could predispose to hypertension in conditions of hyperinsulinaemia. However, in human subjects neither acute hyperinsulinaemia induced 26.2 ± 4.6 mol/kg/min, P = 0.002) associated with a decrease in non-oxidative glucose disposal. NA did not significantly alter 24-h mean systolic or diastolic blood pressure. Fasting glucose, insulin and non-esterified free fatty acid (NEFA) levels remained unchanged, energy expenditure and substrate oxidation were not altered by NA. These results suggest a short term reduction in insulin sensitivity with NA is not accompanied by a change in blood pressure. This may relate to the short duration of treatment, to a dissociation between insulin resistance and hypertension or to other homeostatic mechanisms which prevent blood pressure rising in subjects not predisposed to hypertension. Journal of Human Hypertension (2000) 14, 567-572 by insulin infusion 12 nor chronic hyperinsulinaemia due to insulinoma 13, 14 causes hypertension. Moreover, insulin resistance is not observed in secondary forms of hypertension such as renovascular disease. 15 Thus, uncertainty remains as to whether insulin resistance causes hypertension, and evaluation of this relationship is made difficult by the lack of a prospective model of insulin resistance.
Nicotinic acid (NA) is a B group vitamin which is used for the treatment of hyperlipidaemia. In addition to its effects on lipids, short term administration of NA has been documented to cause significant reductions in insulin sensitivity and hyperinsulinaemia without affecting plasma glucose concentrations. [16] [17] [18] While these changes in carbohydrate metabolism are similar to those observed in essential hypertension, the effect of NA-induced insulin resistance on blood pressure has not been systematically evaluated. The aim of this study was to determine the effects of short term NA administration on insulin sensitivity and blood pressure.
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Materials and methods
Experimental subjects
Seven non-obese healthy volunteers, three males and four females (mean ± s.e.; 33.9 ± 1.8 years; 25.7 ± 0.8 kg/m 2 ) were recruited from the general population. Subjects had no history of diabetes mellitus, pre-existing abnormalities of glucose tolerance, renal disease or hypertension and were on no medications. The study was approved by the Research Ethics Committee of South Eastern Sydney Area Health Service Ethics Committee and all subjects gave informed consent.
A double-blind placebo-controlled study was performed. Medications were concealed in capsules containing either placebo or 250 mg NA (RhonePoulenc Rorer, Kew, Victoria, Australia). In the first phase subjects were randomised to NA or placebo. They received one capsule twice daily on days 1-7 and two capsules twice daily on days 8-14. After a medication free washout period for at least 4 weeks, subjects were crossed over to the alternate treatment for 14 days. Thus during the active treatment phase, subjects received 500 mg NA/day in the first week and 1000 mg NA/day in the second week. The stepped increase in dose was chosen to minimise NA side-effects such as flushing.
Hyperinsulinaemic, euglycaemic glucose clamp and indirect calorimetry
On day 14 of each treatment phase subjects presented at 08.30 following a 12-h overnight fast. Insulin sensitivity was assessed by the hyperinsulinaemic euglycaemic clamp technique. 19, 20 Two cannulas were inserted under local anaesthetic, the first retrogradely into a wrist vein and a heating blanket was placed over the hand to arterialise the venous blood. 21 The second cannula was inserted into the opposite cubital fossa for the insulin and glucose infusions. Subjects then rested comfortably in the recumbent position for at least 40 min in preparation for measurement of basal energy expenditure and substrate oxidation by indirect calorimetry (Deltatrac Metabolic Monitor; Datex Instrumentarium Corp, Helsinki, Finland) which was performed over the next 30-min period as previously described. 22 Following this a primed constant infusion of human insulin (Actrapid HM, Novo-Nordisk, Sydney, Australia) was administered at a rate of 240 pmol/m 2 /min for 120 min to achieve circulating concentrations of insulin in the mid to high physiological range previously shown to completely suppress hepatic glucose output. 23 Blood samples were taken every 5 min from the arterialised line and blood glucose levels were immediately measured on a glucose analyser (Yellowsprings 1500 Sidekick D-Glucose Analyser, Yellow Springs Instrument Co., Yellow Springs, OH, USA). The exogenous glucose infusion was adjusted according to a standard algorithm in order to maintain the blood glucose at 4.5 mmol/L. The glucose infusion rate for the last 60 min was used as an index of insulin sensitivity. The glucose infusion rate was expressed per kg fat free mass (FFM) which was determined by bioelectrical impedance (Biostat 1500, Bodystat Ltd, Isle of Man, UK). Indirect calorimetry was repeated in the last 30 min of the glucose clamp. Samples were drawn every 30 min for measurement of insulin and non-esterified free fatty acid (NEFA).
Ambulatory blood pressure monitoring
Blood pressure was measured over a 24-h period using an automated device (Accutracker II, Suntech Medical Instruments, Raleigh, NC, USA). On day 13 the cuff was placed around the non-dominant arm and worn for 24 h with blood pressure recordings taken every 30 min. Subjects were asked to keep a diary of their daily activity including the period at which they went to sleep. The recordings were analysed with interactive software (Accusoft, Suntech Medical Instruments). Subjects were asked to carry out their normal daily routine. Based on our previous experience using 30-min measurements of blood pressure in normal subjects with ambulatory blood pressure monitoring (ABPM), the standard deviation of differences of repeated measures in systolic blood pressure is 4 mm Hg and for repeated measures of diastolic pressure is 3 mm Hg. 24 During the blood pressure monitoring period a 24-h urine collection was taken for measurement of electrolytes, prostaglandin E and nitrate/nitrite activity.
Forearm blood flow measurement
On day 13 of each treatment phase, forearm blood flow was measured by strain gauge plethysmography as previously described. 25 Briefly, bilateral forearm blood flow was measured by mercury in rubber strain gauge (Hokason, Bellevue, USA) placed 7 cm distal to the olecranon process. Wrist cuffs were inflated to supersystolic pressure to exclude the hand circulation. Forearm blood flow was measured during periods of cyclical inflation and deflation of upper arm cuffs to 40 mm Hg. Subjects were rested for 15 min in the supine position prior to measurements. Measurements were obtained over three separate 5-min recording periods. Forearm blood flow was calculated from the mean of these results.
Laboratory measurements
Serum insulin concentrations were determined by double antibody radioimmunoassay. 26 NEFA was determined by an acyl CoA oxidase based colorimetric method (Wako, Osaka, Japan). The inter-and intra-assay coefficients of variation for insulin were 11% and 4% at 120 pmol/L and for NEFA were 5% and 5% at 500 mol/L. Serum cholesterol and triglyceride levels were measured with an automated enzymatic method. Urinary and plasma nitrate/nitrite concentrations were measured by a modified Griess colour reaction as previously described. The inter-and intra-assay coefficient of variations of this assay were 6% and 6% respectively. Urinary prostaglandin E2 (PGE2) concentration was measure by a commercial radioimmunoassay kit (Dupont NEN research products). The inter-and intra-assay coefficients of variations for measurement of PGE2 were 12.6% and 6.9% respectively.
Statistical analysis
Statistical analysis was performed using the Student's t-test for paired data and ANOVA (StatView SE + Graphics, Abacus Concepts Inc, Berkeley, CA, USA) for unpaired data. Relationships between variables were determined using simple and multiple regression analysis. Based on the standard deviation of the differences of repeated measures of systolic and diastolic pressure, a sample size of seven subjects provided 80% power for detecting a 6-mm change in systolic blood pressure and a 5-mm change in diastolic blood pressure. Results are expressed as mean ± s.e.m.
Results
Mean body weight and percent body fat were not significantly different following placebo or nicotinic acid treatment as shown in Table 1 . Fasting glucose, insulin and NEFA levels were not different between the respective treatments. High-density lipoprotein (HDL) cholesterol levels significantly increased with NA treatment, with a slight but non-significant fall in serum low-density lipoprotein (LDL) while triglycerides were not altered. The mean glucose and insulin concentrations achieved during the hyperinsulinaemic euglycaemic glucose clamps were not significantly different between NA and placebo treatments (Figure 1 ). However, NA treatment reduced whole body insulin sensitivity by 18% as determined by a reduced glucose infusion rate (GIR) to maintain euglycaemia in all seven subjects (Table 2, Figure 2 ). The reduction in GIR was related to a significant reduction (by 31%) in non-oxidative glucose disposed during NA treatment.
There were no significant differences in systolic, diastolic or mean arterial pressure between placebo and NA over 24 h or in the awake or sleeping periods (Table 3, Figure 3 ). Ninety-five percent confidence intervals (95% CI) for systolic blood pressure (110-114.9 vs 109.8-119.5 mm Hg, placebo vs NA) and diastolic blood pressure (80.1-84.5 vs 78.5-85.5 mm Hg) were not different between each phase. 
Results expressed at mean ± s.e.m. *P Ͻ 0.05. Figure 1 Mean (±s.e.m.) glucose and insulin profiles during the hyperinsulinaemic euglycaemic clamp during placebo (squares) and nicotinic acid treatment (circles). Results expressed as mean ± s.e.m. *P = 0.002.
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Figure 2
Glucose infusion rates and non-oxidative glucose disposal measured during the hyperinsulinaemic euglycaemic clamp in the seven subjects during placebo and nicotinic acid treatment (*P = 0.002). Forearm blood flow and forearm vascular resistance were not significantly altered by NA. NA treatment did not significantly affect plasma and urine nitrate/nitrite concentrations or urinary prostaglandin E2 concentrations.
Basal energy expenditure was not significantly different during placebo and NA treatment phases as shown in Table 3 . During the hyperinsulinaemic, euglycaemic glucose clamp energy expenditure rose significantly during placebo treatment consistent with the increase in non-oxidative glucose disposal documented during the clamp. No change in energy expenditure was observed during the hyperinsulinaemic clamp in the NA treatment phase. Basal substrate oxidation was not different between each treatment. Reduced carbohydrate and lipid oxidation was observed during the hyperinsulinaemic, euglycemic clamps during both treatments.
Discussion
Short-term NA treatment significantly reduced insulin sensitivity as documented by an 18% reduction in non-oxidative glucose disposal during the hyperinsulinaemic euglycaemic clamp. The absence of a rise in energy expenditure in NA-treated subjects during the clamp is also consistent with a reduction in non-oxidative glucose disposal in contrast to the placebo phase in which the expected increase in energy expenditure was observed during the clamp. These changes were not associated with any significant change in plasma lipid profiles or lipid oxidation. Hence NA treatment offers a prospective model of insulin resistance. Fasting hyperinsulinaemia was not observed, however, this may be a function of the dose of NA used in this study as fasting hyperinsulinaemia has been documented in subjects treated with 2 g of NA per day. 18 The mechanism of NA-induced insulin resistance remains uncertain although several possible mechanisms have been excluded by this study. Biphasic effects of NA on free fatty acids have been observed during intravenous infusions with an increase in free fatty acids in the first 160 min of NA infusion followed by a slow decline in free fatty acid concentrations. 27 In the longer term, a 'rebound' increase in free fatty acid concentrations has been reported. 28 Increased availability of free fatty acids has been proposed as a possible mechanism by which NA impairs glucose utilisation. However, NA-induced insulin resistance occurred without significant elevation of the fatty acids in this study. Sustained hyperinsulinaemia has been advocated as another possible mechanism by which insulin resistance may occur, 29 however, in the current study insulin resistance occurred in the absence of a significant rise in fasting plasma insulin concentrations. In the rat, NA-induced insulin resistance is associated with a marked shift in fuel utilisation from carbohydrate to lipid metabolism, 30 however, a significant difference in fuel utilisation was not observed in this study. Plasma membrane phospholipid composition and muscle triglyceride levels have a significant relationship with insulin sensitivity 31 and it remains possible that NA-induced insulin resistance is mediated by an effect on plasma membrane phospholipid concentrations and/or lipid content. The effects of NA occurred over a period of days 27, 28 and fasting insulin concentrations returned to baseline approximately 3 days after NA is ceased. As there was a minimum 14-day drug free wash out period between each phase in this study a carryover effect in terms of alteration in insulin sensitivity was unlikely.
Despite the reduction in insulin sensitivity induced by NA, there were no changes in systolic, diastolic or mean arterial pressure determined by 24-h ABPM. The 18% reduction in insulin sensitivity should be sufficient to have a blood pressure effect as non-obese hypertensive subjects are reported to have a 14% reduction in insulin sensitivity compared to controls. 2 There are several possible explanations for the failure of reduced insulin sensitivity to raise blood pressure in these subjects. Firstly the duration of treatment may have been insufficient for hypertension to develop in otherwise normal subjects. Secondly, significant fasting hyperinsulinaemia was not induced by the dose of NA used in this study. While hyperinsulinaemia alone does not elevate blood pressure in normal subjects 12 it remains possible that the haemodynamic effects of hyperinsulinaemia could be modified by insulin resistance itself to produce an increase in blood pressure. Finally, homeostatic responses during NA administration may have offset the effect of the increase in insulin resistance on blood pressure. NA is associated with marked cutaneous vasodilatation which is mediated by prostaglandins, 32 however, in the current study we are unable to document any increase in urinary prostaglandin production or other dilator substances such as nitric oxide. Forearm vascular resistance which reflects vascular resistance in skeletal muscle beds was not significantly reduced by NA.
The other interpretation of these results is that insulin resistance does not cause hypertension. Disassociation between insulin resistance and hypertension has been noted in other models including sustained hyperinsulinaemia-induced insulin resistance in the rat. 29 Although some epidemiological studies suggest a link between insulin resistance and hypertension, recent analysis of data from the Framingham study suggests that insulin resistance alone does not cause all the features of the metabolic Journal of Human Hypertension syndrome. 33 Thus insulin resistance and hypertension may share common genetic or environmental factors which predispose the individual to develop both conditions but also have specific unshared genetic and environmental influences. Further prospective evaluation of the relationship between insulin resistance and blood pressure in human subjects is required to determine whether there is a causative relationship between insulin resistance and hypertension.
